Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms
Standard
Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms. / Reich, Kristian; Thyssen, Jacob P; Blauvelt, Andrew; Eyerich, Kilian; Soong, Weily; Rice, Zakiya P; Hong, H Chih-Ho; Katoh, Norito; Valenzuela, Fernando; DiBonaventura, Marco; Bratt, Tamara A; Zhang, Fan; Clibborn, Claire; Rojo, Ricardo; Valdez, Hernan; Kerkmann, Urs.
in: IMMUNOTHERAPY-UK, Jahrgang 15, Nr. 13, 09.2023, S. 975-980.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms
AU - Reich, Kristian
AU - Thyssen, Jacob P
AU - Blauvelt, Andrew
AU - Eyerich, Kilian
AU - Soong, Weily
AU - Rice, Zakiya P
AU - Hong, H Chih-Ho
AU - Katoh, Norito
AU - Valenzuela, Fernando
AU - DiBonaventura, Marco
AU - Bratt, Tamara A
AU - Zhang, Fan
AU - Clibborn, Claire
AU - Rojo, Ricardo
AU - Valdez, Hernan
AU - Kerkmann, Urs
PY - 2023/9
Y1 - 2023/9
N2 - WHAT IS THIS SUMMARY ABOUT?: Atopic dermatitis (AD, also called atopic eczema) is a skin disease that that can affect a person for a long time and causes red or flaky skin that can be itchy and uncomfortable. Healthcare providers can prescribe medicated creams and ointments to reduce the visible signs and symptoms of AD, but these treatments are not always enough to keep it under control. A new medicine called abrocitinib is taken every day as a tablet. Abrocitinib works by slowing a part of the body's defense mechanism, called immune response, that is not functioning properly in AD. The clinical study described in this plain language summary, called JADE DARE, investigated how well and how safely 26 weeks of treatment with abrocitinib worked in adults with AD compared to an injected medicine, called dupilumab, that is also approved for AD.WHAT WERE THE RESULTS?: The study showed that abrocitinib was more effective than dupilumab in providing itch relief after 2 weeks. In addition, people who were taking abrocitinib for 4 and 16 weeks experienced greater improvement in the visible skin signs of AD than people who were taking dupilumab. The number of people who had health complaints while taking abrocitinib was similar to the number of people who had health complaints while taking dupilumab. Most of these complaints were minor.WHAT DO THE RESULTS MEAN?: Abrocitinib was more effective than dupilumab in quickly improving the signs and symptoms of moderate or severe AD in people who did not show improvement with prescribed medications like creams or ointments. Clinical Trial Registration: NCT04345367 (ClinicalTrials.gov).
AB - WHAT IS THIS SUMMARY ABOUT?: Atopic dermatitis (AD, also called atopic eczema) is a skin disease that that can affect a person for a long time and causes red or flaky skin that can be itchy and uncomfortable. Healthcare providers can prescribe medicated creams and ointments to reduce the visible signs and symptoms of AD, but these treatments are not always enough to keep it under control. A new medicine called abrocitinib is taken every day as a tablet. Abrocitinib works by slowing a part of the body's defense mechanism, called immune response, that is not functioning properly in AD. The clinical study described in this plain language summary, called JADE DARE, investigated how well and how safely 26 weeks of treatment with abrocitinib worked in adults with AD compared to an injected medicine, called dupilumab, that is also approved for AD.WHAT WERE THE RESULTS?: The study showed that abrocitinib was more effective than dupilumab in providing itch relief after 2 weeks. In addition, people who were taking abrocitinib for 4 and 16 weeks experienced greater improvement in the visible skin signs of AD than people who were taking dupilumab. The number of people who had health complaints while taking abrocitinib was similar to the number of people who had health complaints while taking dupilumab. Most of these complaints were minor.WHAT DO THE RESULTS MEAN?: Abrocitinib was more effective than dupilumab in quickly improving the signs and symptoms of moderate or severe AD in people who did not show improvement with prescribed medications like creams or ointments. Clinical Trial Registration: NCT04345367 (ClinicalTrials.gov).
KW - Adult
KW - Humans
KW - Dermatitis, Atopic/drug therapy
KW - Ointments/therapeutic use
KW - Severity of Illness Index
KW - Treatment Outcome
KW - Clinical Studies as Topic
U2 - 10.2217/imt-2022-0306
DO - 10.2217/imt-2022-0306
M3 - SCORING: Review article
C2 - 37254941
VL - 15
SP - 975
EP - 980
JO - IMMUNOTHERAPY-UK
JF - IMMUNOTHERAPY-UK
SN - 1750-743X
IS - 13
ER -
